NLRP6 and graft versus host disease: Drugs affecting the assembly and activation of NLRP6 by directly binding to it and altering its conformation could alleviate or mitigate the different adverse effects when the uncontrolled activation of this inflammasome occurs after gram-positive bacterial infection, GVHD, parasite liver infections, ischemia/reperfusion injury, or glioma.